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Summary
The past 10 years have seen enormous advances in our
understanding of how cytokine signals are mediated in-
tracellularly. Of particular significance was the discovery
of a family of seven Signal Transducer and Activators
of Transcription (STAT) proteins. Each of these has now
been studied in detail, and appropriate gene-disrupted
mouse models are available for all except STAT2 (Leon-
ard and O’Shea 1998). Fetal lethality is observed in
Stat3-deficient mice, and various immunodeficiencies
characterize mice with disrupted Stat1, Stat4, and Stat6
genes, which is consistent with impaired signaling from
the specific cytokines that activate each of these proteins.
The recent characterization of Stat5-deficient mice has
led to several unanticipated findings that point to diverse
biological functions for the two STAT5 forms, STAT5a
and STAT5b. These include roles for one or both STAT5
forms in the immune system, hematopoiesis, sexually
dimorphic growth, mammary development, hair
growth, deposition of adipose tissue, and pregnancy.
Here we review the hormone- and cytokine-activated
signaling pathways in which STAT5 participates and the
extensive evidence, from laboratory animals, that these
factors are required for sex-specific aspects of develop-
ment, including control of body size. Finally, we consider
human growth disorders that may involve defects in
STAT5-dependent signal transduction.
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Cytokine Signal Transduction–JAK/STAT5 Pathway
Cytokines simultaneously activate multiple intracellular-
signaling pathways, including the mitogen-activated
protein (MAP) kinase pathway and the Janus kinase
(JAK)–STAT pathway (fig. 1). The initial step in the JAK-
STAT pathway is the binding of a cytokine to its cognate
cell-surface receptor, which then dimerizes and is trans-
phosphorylated, on specific intracellular tyrosine resi-
dues in the receptor’s cytoplasmic domain, in a reaction
catalyzed by a receptor-associated JAK tyrosine kinase.
Latent cytoplasmic STAT proteins are then recruited to
the activated receptor-kinase complex, via the STAT’s
COOH-terminal SH2 (phosphotyrosine-binding) do-
main, and are phosphorylated on a COOH-termi-
nal–region tyrosine residue and, secondarily, on serine
or threonine residues. The activated STATs then form
homo- or heterodimers via mutual and complementary
SH2-domain interactions, and, within minutes, trans-
locate to the nucleus, where they bind to specific pro-
moter elements and transactivate their target genes
(Leonard and O’Shea 1998; Matsumura et al. 1999).
The promoter elements that are regulated by STAT
homo- or heterodimers contain g-interferon-activated
sequence-like motifs (GAS; TTC(N)3GAA). Because
both the sequences flanking the GAS-like site and the
number of nucleotides in the core vary, these promoter
elements interact preferentially with specific STAT di-
mers. In addition, some promoters contain adjacent
GAS-like motifs that can recruit two STAT dimers. The
NH2-terminal regions of STAT1, STAT4, and STAT5
have been shown to mediate dimerization of juxtaposed
STAT dimers to form tetramers that may enhance target-
gene specificity and binding to low-affinity STAT-binding
sites (Leonard and O’Shea 1998; John et al. 1999).
The STAT family of genes is believed to have arisen
from a single ancestral STAT gene, via a series of gene
and chromosomal duplications (Copeland et al. 1995).
Because the mammalian STAT5 genes are most similar
to the single STAT orthologues found in insects (Barillas-
Mury et al. 1999), it appears that STAT5 is the original
gene, which has retained diverse functions, and that the
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Figure 1 The GH JAK-STAT intracellular signaling pathway. GH binds to dimerized GH receptors, and the receptors and associated
JAK2 phosphotyrosine kinases are phosphorylated (*). Latent cytoplasmic STAT5 proteins are recruited to the receptor-JAK2 complex and are
activated by phosphorylation. Phosphorylated STAT5 proteins homo- or heterodimerize and translocate to the nucleus, where they bind to
target DNA sequences. Intracellular signaling is turned off by several mechanisms. These include: (1) dephosphorylation by phosphatases; (2)
degradation by proteasomes; (3) cytokine induction of SOCS proteins that either bind to receptor or JAK proteins to block subsequent signaling
or mediate interactions with elongins B and C; and (4) PIAS proteins that interact directly with specific STAT proteins (note that PIAS5 has
yet to be identified).
other STAT genes, once duplicated, diverged from that
sequence and adopted specific biological roles. In the
human genome, this history of duplication and mutation
has resulted in three clusters of homologous genes:
STATs 1 and 4 on 2q, STATs 2 and 6 on 12q, and STATs
3, 5a, and 5b on 17q. A relatively recent duplication of
STAT5 is believed to have given rise to the closely related
STAT5a and STAT5b homologues.
The detailed structure within these gene clusters re-
mains uncertain. Physical and genetic data from both
humans and mice suggest that the STAT5a and STAT5b
genes are very close together, with STAT3 probably more
remote; FISH studies on human cells have assigned the
STAT3, STAT5a, and STAT5b genes to different chro-
mosomal bands (17q21 and 17q 11.2, respectively), per-
haps separated by a megabase or more (see GDB Ge-
nome Database), whereas, in mice, genetic mapping does
not resolve these genes (Copeland et al. 1995). Teglund
et al. (1998) suggest that the murine Stat3 and Stat5a
genes may lie within 5 kb of each other. It is interesting
to speculate that the proximity and the high degree of
sequence similarity between STAT5a and 5b may pro-
mote the loss of one of these genes through unequal
crossing-over or gene conversion (Lupski 1998). Al-
though such recombination events are best characterized
at the meiotic level, where they can persist over gener-
ations in a family or a population, they may also occur
mitotically at surprisingly high frequencies, 10-4 or
greater (Tusie-Luna and White 1995), leading to somatic
mosaicism for STAT5a and/or STAT5b function.
Biological Role of STAT5
STAT5 was first identified as a mammary-gland factor
(MGF) that is activated by prolactin and required for
the expression of the milk protein b-casein in cultured
mammary epithelial cells (Wakao et al. 1994). MGF was
subsequently renamed STAT5a when a closely related
gene product, designated STAT5b, was discovered.
STAT5a and STAT5b proteins share ∼90% amino-acid
identity and are activated by a wide range of cytokines
and growth factors (Leonard and O’Shea 1998).
Gene-disruption studies have helped to elucidate the
physiological functions of STAT5a and STAT5b. In
Stat5a-deficient mice, mammary-gland development and
lactation are severely impaired (Liu et al. 1997). These
mice also exhibit lymphohematopoietic defects, includ-
ing defective responsiveness to granulocyte macro-
phage–colony-stimulating factor (GM-CSF) in bone
marrow–derived macrophages and defective IL-2–in-
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duced receptor a-chain expression in T cells (Leonard
and O’Shea 1998; Teglund et al. 1998). By comparison,
the phenotypes of Stat5b-deficient mice indicate that this
factor affects a wider range of biological functions. De-
fects in these animals include altered hair-growth cycles
and adipose-tissue deposition, reproductive failure, im-
munologic defects, impaired mammary-gland develop-
ment and lactation, and loss of sexually dimorphic body-
growth rates and liver gene expression (Udy et al. 1997;
Imada et al. 1998; Teglund et al. 1998; Park et al. 1999).
When the Stat5a and Stat5b genes are both disrupted,
the phenotype is similar to the combined phenotypes
resulting from the individual gene disruptions, with ad-
ditional loss of functions associated with growth hor-
mone or prolactin, and impaired peripheral T-cell acti-
vation by IL-2 (Teglund et al. 1998; Moriggl et al. 1999).
Thus, as summarized in table 1, STAT5a and STAT5b
have nonredundant, as well as redundant, function.
While some of the divergent phenotypic effects of the
two mutations may result from known tissue-specific
differences in the relative abundance of STAT5a- and
STAT5b-protein expression (e.g., STAT5 TAT5b ina 1 S
mammary gland, versus STAT5 TAT5a in liver), theb 1 S
two STAT5 proteins exhibit distinct serine-phosphory-
lation patterns and DNA-binding-site preferences (Ver-
dier et al. 1998; Yamashita et al. 1998). Multiple forms
of STAT5a and STAT5b, resulting from degradation or
alternative splicing, are also present in some tissues. The
roles of these STAT5 forms are not fully understood, but
COOH-terminal–truncated STAT5 variants may act in
a dominant negative manner to inhibit STAT5-depen-
dent signal transduction (Leonard and O’Shea 1998). It
also seems likely that transcriptional activation of at
least some STAT5 target genes may exhibit specific re-
quirements for STAT5a homodimers, STAT5b homo-
dimers, or STAT5a/STAT5b heterodimers (Verdier et al.
1998; Park et al. 1999).
Termination of STAT Signaling
Recent studies have revealed a number of potential
mechanisms by which hormone- or cytokine-stimulated
STAT signals can be turned off. First, activated STAT
proteins, like many cytoplasmic or nuclear proteins, are
subject to ubiquitin-dependent degradation mediated by
the proteasome (Leonard and O’Shea 1998; Gebert et
al. 1999b). Second, the SH2 domain–containing tyrosine
phosphatases SHP-1 and SHP-2 may dephosphorylate
and, hence, inactivate STAT proteins (Ram and Waxman
1997; You et al. 1999). Third, STAT proteins may be
inactivated by interaction with several classes of pro-
teins, including the protein inhibitor of activated STAT
(PIAS) proteins and the suppressor of cytokine-signaling
proteins (SOCS; also known as STAT-induced STAT in-
hibitors [SSI] and cytokine-inducible SH2-containing
proteins [CIS]). PIAS1 and PIAS3 bind directly to STATs
1 and 3, respectively (Chung et al. 1997; Liu et al. 1998),
and, although no PIAS5 has been identified as yet, PIAS
proteins may well exist for each of the STAT proteins.
SOCS proteins contain a COOH-terminal–conserved
SOCS box that mediates interactions with elongins B
and C and that may affect the rate of proteasomal-pro-
tein degradation (Zhang et al. 1999). A subgroup of the
SOCS proteins also contains SH2 domains that mediate
binding to phosphotyrosine residues on receptors or on
other STATs (Hilton et al. 1998). SOCS proteins form
part of a classic negative-feedback loop, in that their
expression is induced by cytokines and they inhibit signal
transduction by binding to the cytokine receptor or JAK
kinase. STAT5a or STAT5b is required for the expression
of CIS in the murine ovary and medullary thymocytes
(Teglund et al. 1998; Moriggl et al. 1999), and STAT5b
is required for the growth hormone (GH)–induced ex-
pression of SOCS-2 and SOCS-3 mRNA in the mouse
liver (H. W. Davey et al., unpublished observations). In
addition to impaired JAK-STAT signaling, a defect in
STAT5 may, therefore, cause cytokine hypersensitivity
or, perhaps, hyperstimulation (from prolonged signaling
via the MAP kinase or via alternative pathways), due to
impaired or reduced induction of SOCS genes that nor-
mally feed back to turn off the initial cytokine signal.
STAT5b and Sexually Dimorphic Body-Growth Rates
In rats, mice, and certain other species, the expression
of a number of liver-expressed genes is highly sexually
dimorphic. This sex difference is primarily determined
by plasma GH profiles, which are sexually dimorphic in
many species, and is only secondarily regulated by other
hormones. Although more pronounced differences can
be seen in some species (e.g., rats), the consistent char-
acteristic that defines the male plasma GH pattern is a
period of negligible GH for at least 1 h between the
pulses of GH. The longer GH interpulse interval that
occurs in males, compared with females, is responsible
for the sex differences in liver gene expression and for
the sexually dimorphic whole-body growth patterns that
emerge at puberty (Waxman and Chang 1995). In rats,
exposure to androgens during the first three days of life
is sufficient to set (“imprint”) the male-specific pituitary
GH secretory pattern that emerges at puberty. This an-
drogen-imprinted adult GH pattern is, in turn, respon-
sible for inducing the expression in liver of male-specific
genes and for suppressing the expression of genes nor-
mally restricted to females. Nearly continuous GH ex-
posure, a characteristic of adult female rats, may also
induce the expression of other liver-expressed genes that
are associated with females (Waxman 1988; Waxman et
al. 1991).
The involvement of Stat5b in GH signaling was first
Table 1
Functions of STAT5, Identified by Analyzing Phenotypes of STAT5a-, STAT5b-, and STAT5a/b-Deficient Mice
Area of Function STAT5a/ STAT5b/ Additional Effects in STAT5a/b/ Mice
Sexual dimorphism of
gene expression
and growth
Some female-specific proteins decreased in liver Sexually dimorphic growth and liver gene expression
decreased in males; some female-specific proteins de-
creased in liver; serum insulin-like growth factor (IGF)-1
Growth of both males and females
further depressed; expression of both
male- and female-specific genes in
the liver decreased; serum IGF-1
decreased
Mammary gland Impaired lobuloalveolar development during
pregnancy; whey acidic protein and a-lactal-
bumin decreased
Impaired mammary development; failure of lactation; ex-
pression of all the major milk proteins decreased
Not examined (infertile)
Hematopoiesis/im-
mune functions
Responsiveness of bone marrow–derived mac-
rophages to GM-CSF decreased; T cells as-
sociated with defective interleukin (IL)-2 sig-
naling decreased; defective GM-CSF–induced
proliferation of bone-marrow macrophages;
natural killer (NK) cells decreased (normal
function)
Response of splenocytes to IL-2 and IL-15 decreased, re-
sulting in decreased NK cells; small decrease in thymo-
cytes and splenocytes
Response to IL-3 and IL-5 in bone
marrow–derived macrophages de-
creased; T cells decreased; numbers
of pre-B and B-cells decreased; num-
bers of neutrophils increased; re-
sponse of bone marrow–derived
macrophages to IL-7 decreased; im-
paired peripheral T-cell activation by
IL-2
Reproduction Normal? Failure of reproduction due to abortion; pregnancy can be
maintained by exogenous progesterone in some mice
Infertility because of failure to main-
tain a functional corpus lutea
Hair growth No data Altered hair growth cycles; extended telogen before growth
of the second coat of hair
No data
Fat deposition Fat decreased Amounts of adipose tissue in young mice decreased; obesity
in some older mice
Fat decreased (epididymal fat pads ap-
proximately one-fifth that of wild
type)
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recognized by comparing liver nuclear-protein tyrosine-
phosphorylation patterns in male and female rats. In-
termittent plasma GH pulses stimulate tyrosine phos-
phorylation and nuclear translocation of Stat5b in intact
male rats while the more continuous presence of GH in
female rats down-regulates the Stat5b signaling pathway
(Waxman et al. 1995; Gebert et al. 1999a). Experiments
using a rat-liver cell line indicate that Stat5b is deacti-
vated by tyrosine dephosphorylation and then cycles
from the nucleus back to the cytoplasm, at the end of
a GH pulse, to be reutilized. Activated Stat5b is signif-
icantly more abundant in liver from males than in liver
from females, and it is reduced to negligible levels in
hypophysectomized male rats but is restored by GH
treatment (Waxman et al. 1995) under conditions that
mimic the male pulsatile GH-secretion pattern. Overall,
expression of Stat5b in liver is up to 10-fold greater than
that of Stat5a (Park et al. 1999). However, Stat5a ex-
hibits the same preferential activation by male plasma
GH pulses that is seen in Stat5b (Choi and Waxman, in
press).
Thus, the simplest explanation for the phenotype of
Stat5b gene-disrupted male mice is that they have an
impaired cellular response to the pulsatile pattern of pi-
tuitary GH release. This impaired GH-pulse responsive-
ness would account for the observed feminization of
pubertal body-growth rates and the loss of male-specific
liver P450 expression seen in Stat5b-deficient male mice.
It also can explain the apparent increase, in males, of
female-predominant liver gene products to near-female
levels (Udy et al. 1997). To confirm that these are, in
fact, effects of a defect in the cellular response to the
plasma pattern of GH secretion, rather than changes in
the sexually dimorphic pattern of pituitary GH secre-
tion, we hypophysectomized young male Stat5b-defi-
cient and wild-type mice and then treated them with
pulses of GH to mimic the male plasma GH pattern.
Whereas GH pulse injections restored male growth rates
and a male pattern of liver gene expression in hypo-
physectomized wild-type mice, no such restoration was
achieved in hypophysectomized Stat5b-knockout mice
(H. W. Davey et al., unpublished experiments). These
findings demonstrate that STAT5b-deficient mice do, in-
deed, have impaired GH intracellular signaling. Never-
theless, there is some evidence to suggest that GH se-
cretion may be increased in STAT5b-deficient mice
(Luckman et al. 1998).
STAT5 and Liver Cytochrome P450 Gene Expression
Cytochrome P450 is a large superfamily of monooxy-
genase enzymes that participate in a wide range of met-
abolic processes, including cholesterol metabolism, bile-
acid synthesis and metabolism, steroid hormone hy-
droxylation, and the metabolism of drugs and toxic
chemicals. In many instances, P450 metabolism leads to
detoxification and elimination of foreign chemicals, but,
in other cases, it results in the formation of toxicolog-
ically or pharmacologically active metabolites. Several
liver-expressed P450 enzymes have dual specificities;
they oxygenate foreign chemicals, but also display nar-
row stereoselectivities for hydroxylation of testosterone
and other endogenous steroids (Waxman 1988; Wax-
man and Chang 1995).
Animal experiments, principally in rats, have revealed
that expression of a number of these P450 enzymes is
sex-dependent and regulated by GH secretory patterns.
Particular attention has been paid to members of the
CYP2 and CYP3 families and to their involvement in
hepatic steroid hormone hydroxylation, which differs
for each sex and is also subject to postnatal develop-
mental control (Waxman and Chang 1995). Rats have
exaggerated sex differences in drug metabolism, com-
pared with mice and humans, and have, therefore, been
used as a model to study mechanisms regulating this
dimorphism (Shapiro et al. 1995). Nevertheless, mice
exhibit marked male-female differences in the liver pat-
terns of expression of steroid hydroxylase P450s (Sha-
piro et al. 1995) and of several non-P450 liver enzymes
that are also dimorphic in rats. Intriguingly, the actual
patterns and levels of enzymes that are sexually dimor-
phic vary markedly from species to species, and even
from one mouse strain to another. Our analyses of CYP-
expression patterns in Stat5a- and Stat5b-deficient mice
have shown that Stat5b is required to maintain normal
sexually dimorphic GH responses. While Stat5a is fully
dispensable for the male pattern of liver gene expression,
both Stat5a and Stat5b are required for the expression
of certain female-specific, GH-regulated liver gene prod-
ucts (Udy et al. 1997; Park et al. 1999). A simple in-
terpretation of these data is that STAT5b homodimers
mediate GH pulse-regulated gene expression, whereas
STAT5a-STAT5b heterodimers regulate the expression
of some female-specific GH-regulated genes.
As a consequence of these sex differences in liver P450
gene expression, males and females may differ substan-
tially in rates of drug metabolism. Although major sex-
based differences in hepatic P450 profiles have not been
observed in humans, such differences could be masked
by much larger differences between individuals, associ-
ated with P450 polymorphisms and P450 induction
caused by exposure to foreign chemicals. Nevertheless,
human P450-associated drug-metabolism activities are
determined in part by age, sex, and/or GH status
(Cheung et al. 1996). One would predict, based on the
animal data, that individual variations in the efficacy of,
or actual dysfunctions in, STAT5b signaling pathways
could have significant effects on the patterns of human
liver-enzyme expression. Further study is required to as-
certain whether this is a fundamental contributing cause
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to individual variations in drug sensitivities/toxicities,
along with the well-established variations arising from
genetic and environmental factors (Wormhoudt et al.
1999).
STAT5 and Human Growth Defects
Based on the phenotype of the STAT5b-deficient
mouse, one would predict that humans with a dysfunc-
tional STAT5b protein, or a defect in STAT5b-dependent
signaling, would have discernible pubertal growth de-
fects. More specifically, at the molecular level, one would
expect that the actual defect would be in the intracellular
responses to pulsatile GH signaling and that such pa-
tients would retain both functional GH receptors and
circulating serum GH-binding protein. Some patients
with Laron syndrome display precisely these character-
istics (MIM 245590). While the classic (type I) Laron
syndrome is caused by dysfunction of the GH receptor,
this nonclassic (type II) Laron-type dwarfism is attrib-
uted to postreceptor defects in signal transduction. In-
deed, preliminary work by Freeth et al. (1998) suggests
that STAT5 activity is dysfunctional in fibroblasts iso-
lated from affected individuals in one such family af-
fected by Laron syndrome. Unfortunately, genetic het-
erogeneity complicates the study of this extremely rare
disorder (Adam et al. 1981), and, in another family with
Laron syndrome type II, STAT5 appears to function nor-
mally (Clayton et al. 1999). Of less certain connection
with STAT5b dysfunction, but certainly worthy of in-
vestigation, is the relatively large number of idiopathic
short-stature defects, some of which have some symp-
toms similar to those of Laron syndrome (Attie et al.
1995).
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